Though it is widely prescribed for improving sleep of children with autism and other neurogenetic disorders, there is a need for practical guidance to clinicians on the use of melatonin for managing insomnia in this population. Because data were either lacking or inconclusive, a task force was established by the International Pediatric Sleep Association (IPSA) to examine the literature based on clinical trials from 2012 onwards. A summary of evidence pertaining to melatonin's utility and potential side effects, practice-related caveats, and insights for use are published herewith.
Melatonin use in managing insomnia in children with autism and other neurogenetic disorders - An assessment by the international pediatric sleep association (IPSA) / Kotagal, S.; Malow, B.; Spruyt, K.; Wang, G.; Bolanos Almeida, C. E.; Tavera Saldana, L. M.; Blunden, S.; Narang, I.; Ipsiroglu, O. S.; Bruni, O.; Strazisar, B. G.; Simakajornboon, N.; Nunes, M. L.; Cortese, S.. - In: SLEEP MEDICINE. - ISSN 1389-9457. - 119:(2024), pp. 222-228. [10.1016/j.sleep.2024.04.008]
Melatonin use in managing insomnia in children with autism and other neurogenetic disorders - An assessment by the international pediatric sleep association (IPSA)
Bruni O.;
2024
Abstract
Though it is widely prescribed for improving sleep of children with autism and other neurogenetic disorders, there is a need for practical guidance to clinicians on the use of melatonin for managing insomnia in this population. Because data were either lacking or inconclusive, a task force was established by the International Pediatric Sleep Association (IPSA) to examine the literature based on clinical trials from 2012 onwards. A summary of evidence pertaining to melatonin's utility and potential side effects, practice-related caveats, and insights for use are published herewith.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
